Your browser doesn't support javascript.
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Samira Fafi-Kremer; Timothee Bruel; Yoann Madec; Rebecca Grant; Laura Tondeur; Ludivine Grzelak; Isabelle Staropoli; Francois Anna; Philippe Souque; Catherine Mutter; Nicolas Collongues; Alexandre Bolle; Aurelie Velay; Nicolas Lefebvre; Marie Mielcarek; Nicolas Meyer; David Rey; Pierre Charneau; Bruno Hoen; Jerome De Seze; Olivier Schwartz; Arnaud Fontanet.
  • Samira Fafi-Kremer; CHRU Strasbourg
  • Timothee Bruel; Institut Pasteur
  • Yoann Madec; Institut Pasteur
  • Rebecca Grant; Institut Pasteur
  • Laura Tondeur; Institut Pasteur
  • Ludivine Grzelak; Institut Pasteur
  • Isabelle Staropoli; Institut Pasteur
  • Francois Anna; Pasteur-Theravectys
  • Philippe Souque; Institut Pasteur
  • Catherine Mutter; CHRU Strasbourg
  • Nicolas Collongues; CHRU Strasbourg
  • Alexandre Bolle; CHRU Strasbourg
  • Aurelie Velay; CHRU Strasbourg
  • Nicolas Lefebvre; CHRU Strasbourg
  • Marie Mielcarek; CHRU Strasbourg
  • Nicolas Meyer; CHRU Strasbourg
  • David Rey; CHRU Strasbourg
  • Pierre Charneau; Institut Pasteur
  • Bruno Hoen; Institut Pasteur
  • Jerome De Seze; Institut Pasteur
  • Olivier Schwartz; Institut Pasteur
  • Arnaud Fontanet; Institut Pasteur
Preprint in English | medRxiv | ID: ppmedrxiv-20101832
ABSTRACT
BackgroundThe serologic response of individuals with mild forms of SARS-CoV-2 infection is poorly characterized. MethodsHospital staff who had recovered from mild forms of PCR-confirmed SARS-CoV-2 infection were tested for anti-SARS-CoV-2 antibodies using two assays a rapid immunodiagnostic test (99.4% specificity) and the S-Flow assay ([~]99% specificity).The neutralizing activity of the sera was tested with a pseudovirus-based assay. ResultsOf 162 hospital staff who participated in the investigation, 160 reported SARS-CoV-2 infection that had not required hospital admission and were included in these analyses. The median time from symptom onset to blood sample collection was 24 days (IQR 21-28, range 13-39). The rapid immunodiagnostic test detected antibodies in 153 (95.6%) of the samples and the S-Flow assay in 159 (99.4%), failing to detect antibodies in one sample collected 18 days after symptom onset (the rapid test did not detect antibodies in that patient). Neutralizing antibodies (NAbs) were detected in 79%, 92% and 98% of samples collected 13-20, 21-27 and 28-41 days after symptom onset, respectively (P=0.02). ConclusionAntibodies against SARS-CoV-2 were detected in virtually all hospital staff sampled from 13 days after the onset of COVID-19 symptoms. This finding supports the use of serologic testing for the diagnosis of individuals who have recovered from SARS-CoV-2 infection. The neutralizing activity of the antibodies increased overtime. Future studies will help assess the persistence of the humoral response and its associated neutralization capacity in recovered patients.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study Topics: Long Covid Language: English Year: 2020 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study Topics: Long Covid Language: English Year: 2020 Document Type: Preprint